Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia.
In this report we present a method for purging acute myeloid leukaemia progenitors (AML-CFU) from autologous marrow grafts. Previous studies using flow cytometry and cell sorting had indicated that the monoclonal antibody (MCA) Vim-2 reacts strongly with AML-CFU in a significant number of cases, whereas the majority of normal bone marrow precursors are Vim-2 negative. To investigate the applicability of Vim-2 for selective purging, we performed complement-dependent cytotoxicity experiments and determined the specific lysis of AML-CFU. In 11 of 17 patients, 97.5 +/- 4% (mean +/- SD) of AML-CFU were killed following immune-mediated lysis. Multi-lineage normal haematopoietic progenitors (CFU-GEMM) were not significantly affected by the MCA Vim-2-mediated complement lysis. These data suggest that the MCA Vim-2 is a useful reagent for the elimination of residual AML progenitor cells from remission bone marrow in patients subjected to autologous marrow transplantation.
Delwel
R
R
Dr. Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
Bot
F
F
Knapp
W
W
Löwenberg
B
B
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000943:Antigens, Differentiation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D003165:Complement System Proteins; D003602:Cytotoxicity, Immunologic; D005434:Flow Cytometry; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D003165:Complement System Proteins